

## Supporting Information

### ***N*-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as novel selective human cannabinoid type 2 receptor (hCB2R) ligands. Insights into the mechanism of receptor activation/deactivation.**

Eleonora Gianquinto<sup>1</sup>, Federica Sodano<sup>1,2</sup>, Barbara Rolando<sup>1</sup>, Ali Mokhtar Mahmoud<sup>3</sup>, Magdalena Kostrzewa<sup>3</sup>, Marco Allarà<sup>3</sup>, Poulami Kumar<sup>3</sup>, Francesca Spyrakis<sup>1</sup>, Alessia Ligresti<sup>3,\*</sup>, Konstantin Chegaev<sup>1,\*</sup>

<sup>1</sup> Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy;

<sup>2</sup> Department of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy;


<sup>3</sup> National Research Council of Italy, Institute of Biomolecular Chemistry, 80078 Pozzuoli, Italy

Corresponding authors: Alessia Ligresti, [aligresti@icb.cnr.it](mailto:aligresti@icb.cnr.it) ; Konstantin Chegaev, [konstantin.chegaev@unito.it](mailto:konstantin.chegaev@unito.it).


### Table of contents

<b>Figure S1.</b> Competition radioligand binding assay at hCB2R.	S2
<b>Figure S2.</b> Chemical structure of compounds 47, 49, 51, 53 from Mugnaini <i>et al.</i>	S3
<b>Figure S3.</b> Docking poses of compound 47 and 49 in 5zty, and of 51 and 53 from Mugnaini <i>et al.</i> in 6kpc	S4
<b>Figure S4.</b> Docking poses of compounds 10e and 10g in 6kpc	S5
<b>Figure S5.</b> Docking poses of compound 12b in 5zty	S6
<b>Figure S6.</b> Alignment of 12e and AM10257 in 5zty	S7
<b><sup>1</sup>H and <sup>13</sup>C NMR spectra</b> of all final compounds	S8-S50


**Figure S1.** Competition radioligand binding assay of **10d** (A), **10e** (B), **10f** (C), **10g** (D), **10h** (E), **12a** (F), **12b** (G), **12e** (H) and **13** (I) at hCB2R, using [ $^3$ H]CP55 940. Data are reported as mean  $\pm$  SE of three independent experiments conducted in duplicate.




**Figure S2.** Chemical structure of compounds 47 (a), 49 (b), 51 (c) and 53 (d) from Mugnaini et al. [12].




**Figure S3.** Docking poses of compound 49 (dark teal sticks, **a**) and compound 47 (grey sticks, **b**) in the antagonist conformation of hCB2R (PDB ID 5zty, light orange cartoon), and compound 51 (lilac sticks, **c**) and compound 53 (magenta sticks, **d**) in the agonist conformation of hCB2R (PDB ID 6kpc, light green cartoon). Compounds have been reported and described by Mugnaini et al. [12]. Residues lining the binding site are represented as capped sticks and labelled, helices are numbered as TM1-7.



**Figure S4.** Docking poses of compounds **10e** (salmon pink, **a**) and **10g** (cyan, **b**) in the agonist conformation of hCB2R receptor (PDB ID: 6kpc, light green cartoon). Residues lining the binding site are represented as capped sticks and labelled, helices are numbered as TM1-7. Hydrogen bonds are represented as black dashed lines.



**Figure S5.** Docking poses of compound **12b** in the antagonist conformation of CB2R receptor (PDB ID 5zty). Residues lining the binding site are represented as capped sticks and labelled, transmembrane helices are numbered as TM1-7. Hydrogen bonds are represented as black dashed lines.



**Figure S6.** Alignment of **12e** docking pose (yellow) and antagonist AM10257 (green) in the antagonist-like state (PDB ID 5zty). Protein is coloured in light orange cartoon, residues lining the binding site are represented as capped sticks and labelled, helices are numbered as TM1-7.

